0000010456false00000104562024-10-082024-10-080000010456exch:XCHIbax:CommonStock1.00PerValueMember2024-10-082024-10-080000010456exch:XNYSbax:CommonStock1.00PerValueMember2024-10-082024-10-080000010456exch:XNYSbax:GlobalNotes13Due2025Member2024-10-082024-10-080000010456exch:XNYSbax:GlobalNotes13Due2029Member2024-10-082024-10-08

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
PURSUANT TO SECTION 13 OR 15(D)
OF THE SECURITIES EXCHANGE ACT OF 1934
Date of Report (Date of earliest event reported): October 8, 2024
Baxter International Inc.
(Exact name of registrant as specified in its charter)
Delaware
(State or other jurisdiction of incorporation)
1-444836-0781620
(Commission File Number)(I.R.S. Employer Identification No.)
One Baxter Parkway, Deerfield, Illinois
60015
(Address of principal executive offices)(Zip Code)
(224)948-2000
(Registrant’s telephone number, including area code)
(Former name or former address, if changed since last report)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
☐    Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
☐    Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
☐    Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
☐    Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
Securities registered pursuant to Section 12(b) of the Act:
Title of each classTrading Symbol(s)Name of each exchange on which registered
Common Stock, $1.00 par valueBAX (NYSE)New York Stock Exchange
NYSE Chicago
1.3% Global Notes due 2025BAX 25New York Stock Exchange
1.3% Global Notes due 2029BAX 29New York Stock Exchange
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter):
☐ Emerging growth company
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act:   ☐


Item 7.01     Regulation FD Disclosure.
On September 29, 2024, Baxter International Inc., a Delaware corporation (the “Company” or “Baxter”) issued a press release regarding the impact of Hurricane Helene, which brought unprecedented rain and extensive flooding to Western North Carolina, on the operations of its North Cove facility in Marion, N.C. Baxter’s North Cove facility was affected by flooding due to the storm and is currently closed for production while the Company undertakes related remediation efforts.
The Company is actively working with customers, regulators and other stakeholders to manage inventory and minimize disruption to patient care as it works to fully restore its North Cove manufacturing operations. This work includes implementing allocations, which limit customer orders based on historical ordering and medical necessity as well as available and projected inventory, reallocating capacity from certain other Baxter facilities and working with U.S. Food and Drug Administration to provide for the temporary importation of certain Baxter products.
On October 8, 2024, based on the current status of its remediation efforts and the Company’s expectations of its ability to reallocate capacity from certain other Baxter facilities and to initiate temporary importation on certain products, Baxter shared that its goal is to restart North Cove production in phases and to be at 90% to 100% allocation of certain intravenous solution product codes by the end of 2024.
The Company plans on providing periodic updates regarding the status of its remediation efforts and supply continuity matters on its website (www.baxter.com/baxter-newsroom/hurricane-helene-updates) and to provide other updates (including with respect to the related estimated financial impact on its operations) as part of its third quarter earnings announcement.
This Form 8-K may contain forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, including with respect to statements regarding the status and remediation of Baxter’s North Cove facility, including targets to restart production and related product allocation goals, the related timing and the estimated impact on its financial performance and results of operations. Use of the words “may,” “will,” “would,” “could,” “should,” “believes,” “estimates,” “projects,” “potential,” “expects,” “plans,” “seeks,” “intends,” “evaluates,” “pursues,” “anticipates,” “continues,” “designs,” “impacts,” “affects,” “forecasts,” “target,” “outlook,” “initiative,” “objective,” “designed,” “priorities,” “goal,” or the negative of those words or other similar expressions is intended to identify forward-looking statements that represent its current judgment about possible future events. These forward-looking statements are based on assumptions about many important factors, including the following, which could cause actual results to differ materially from those in the forward-looking statements: risks related to further disruption due to Hurricane Helene or other storm-related events (including Hurricane Milton); the Company’s ability to import and distribute product from other Baxter facilities (in connection with temporary importations, the reallocation of manufacturing capacity or otherwise); the receipt of any necessary regulatory or other approvals required to reopen all or a portion of the North Cove facility; physical, environmental or other obstacles identified during the course of the ongoing remediation (including with respect to the availability of third party contractors and any equipment, transportation or other supplies needed to support the remediation efforts); and risks identified in Baxter’s most recent filings on Form 10-K, Form 10-Q and other filings with the U.S. Securities and Exchange Commission (the “SEC”), all of which are available on Baxter’s website. Baxter does not undertake to update its forward-looking statements or any of the statements contained in this Form 8-K.
None of the information or data included on the Baxter website referenced in this Form 8-K or accessible at this link is incorporated into, and will not be deemed to be a part of, this Form 8-K or any of the Company’s other filings with the SEC.
The information contained in this Item 7.01 shall not be deemed to be “filed” for the purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”) or otherwise subject to the liabilities of such section, nor will such information be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended (the “Securities Act”), or the Exchange Act, except as may be expressly set forth by specific reference in such filing.


SIGNATURE
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.
Date: October 9, 2024
BAXTER INTERNATIONAL INC.
By:/s/ Ellen K. Bradford
Name:Ellen K. Bradford
Title:Senior Vice President and Corporate Secretary


v3.24.3
Document and Entity Information Document
Oct. 08, 2024
Entity Information [Line Items]  
Document Type 8-K
Document Period End Date Oct. 08, 2024
Entity Registrant Name Baxter International Inc.
Entity Central Index Key 0000010456
Amendment Flag false
Entity Incorporation, State or Country Code DE
Entity File Number 1-4448
Entity Tax Identification Number 36-0781620
Entity Address, Address Line One One Baxter Parkway
Entity Address, City or Town Deerfield
Entity Address, State or Province IL
Entity Address, Postal Zip Code 60015
City Area Code 224
Local Phone Number 948-2000
Written Communications false
Soliciting Material false
Pre-commencement Tender Offer false
Pre-commencement Issuer Tender Offer false
Entity Emerging Growth Company false
NEW YORK STOCK EXCHANGE, INC. | Common Stock, $1.00 Per Value  
Entity Information [Line Items]  
Title of 12(b) Security Common Stock, $1.00 par value
Trading Symbol BAX (NYSE)
Security Exchange Name NYSE
NEW YORK STOCK EXCHANGE, INC. | 1.3% Global Notes due 2025  
Entity Information [Line Items]  
Title of 12(b) Security 1.3% Global Notes due 2025
Trading Symbol BAX 25
Security Exchange Name NYSE
NEW YORK STOCK EXCHANGE, INC. | 1.3% Global Notes due 2029  
Entity Information [Line Items]  
Title of 12(b) Security 1.3% Global Notes due 2029
Trading Symbol BAX 29
Security Exchange Name NYSE
CHICAGO STOCK EXCHANGE, INC | Common Stock, $1.00 Per Value  
Entity Information [Line Items]  
Title of 12(b) Security Common Stock, $1.00 par value
Trading Symbol BAX (NYSE)
Grafico Azioni Baxter (NYSE:BAX)
Storico
Da Nov 2024 a Dic 2024 Clicca qui per i Grafici di Baxter
Grafico Azioni Baxter (NYSE:BAX)
Storico
Da Dic 2023 a Dic 2024 Clicca qui per i Grafici di Baxter